THE EFFECT OF EICOSAPENTAENOIC ACID (EPA) ON BIOMARKERS OF GROWTH AND VASCULARITY IN HUMAN COLORECTAL CANCER LIVER METASTASES - The Effects of EPA on Human Colorectal Cancer Liver Metastases

Phase 1

• Conditions: Colorectal cancer liver metastases; MedDRA version: 12.0 Level: LLT Classification code 10027483 Term: Metastatic neoplasm of liver

• Registration Number: EUCTR2009-015903-22-GB
• Lead Sponsor: niversity of Leeds

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-06-28
• Study Completion: 2011-11-28
• Last Update Posted: 25 November 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 88

Inclusion Criteria

Age >18 years
Either sex
Presence of colorectal cancer liver metastasis(es) deemed appropriate for liver resection
Duration between decision to perform liver resection and surgery >2 weeks
Ability to give written informed consent and follow study protocol
Telephone contact possible
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Neo-adjuvant chemotherapy for CRC liver metastasis
Chemotherapy for any cancer in the previous 3 months
Known bleeding diathesis or anticoagulation therapy
Fish or seafood allergy
Use of fish oil supplements (eg. cod liver oil) and unwilling to stop for the duration of the study
Pregnancy
Corticosteroid or non-steroidal anti-inflammatory (NSAID) use (except low dose aspirin)
Renal impairment (serum creatanine >150micromol/l)
Active inflammatory disease (e.g. Inflammatory Bowel Disease, Rheumatoid Arthritis)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified